Abstract Benign prostate hyperplasia (BPH) is a common condition in aged men and result from prolong chronic inflammation in prostate gland. Cytokines are important molecules responsible for inflammation. Single nucleotide polymorphisms (SNPs) in promoter region of cytokine genes have been shown to alter the level of cytokines.
Introduction
Benign prostate hyperplasia (BPH) is a very common condition, yet little is known about the etiology and pathogenesis of the condition, and the only definitive risk factors are an intact androgen system and aging and inflammation [1] [2] [3] . Although many epidemiological clinical studies have been conducted worldwide for last 20 years, but incidence of clinical BPH remains difficult to determine. However, its prevalence is age dependent with histological evidence of BPH rarely under 50 years of age, but by age 80 virtually all men have some histological evidence of the process.
Chronic inflammation has been implicated in the development of complex human diseases including BPH. Cytokines are important inflammatory markers secreted in response to tumors and often by tumor cells. Several polymorphisms in cytokines, both functional and nonfunctional have already been reported to have positive associations with prostatic growth but surprisingly BPH still lacks a definitive and complete picture of subtle genetic polymorphisms that would be useful for early diagnosis.
The role of different cytokines in BPH is not well established. Genetic association studies are likely to shed light on our current understanding of their roles in the risk of BPH. The present study has therefore undertaken to assess the risk of BPH with pro and anti-inflammatory cytokine genes such as IL-1B, TNF-A, IFN-G, IL-1RN, IL-4, IL-6, IL10, and TGF-B in a case control study in north Indian Population. An attempt was also made to find risk for BPH for various lifestyle related risk factor such as tobacco smoking, tobacco chewing and alcohol consumption in relation to these gene variants.
Materials and Methods
The participants in this study (BPH patients and controls) were unrelated individuals of similar ethnicity from Lucknow and other adjoining cities, visiting department of Urology at the tertiary referral centre of North India during May 2005 to December 2007. All of the BPH patients had various degrees of lower urinary tract symptoms and showed an apparent prostatic enlargement by digital rectal examination. The PSA levels were measured in all of the BPH patients, and men with elevated PSA levels ([4.0 ng/ ml). Most subjects were enrolled in our ongoing project identifying the gene polymorphisms affecting the prostate cancer (PCa) development and progression. The clinical presentation of patients was lower urinary tract symptoms with a severe American Urological Association symptom score (greater than 20). The patients with a serum prostatespecific antigen (PSA) level greater than 4 ng/ml underwent transrectal ultrasound-guided prostatic True-Cut biopsy to rule out PCa. Cases having previous history of cancer were excluded. Only symptomatic and histologically proven BPH cases (n = 151) were enrolled in the study after informed consent. The study was accorded approval by the ethical committee of institute and informed consent was obtained from all subjects. Blood was collected by veni-puncture in sterile, 5 ml ethylenediamine tetra-acetic acid (EDTA) tubes and stored at -20°C.
Healthy men (n = 256) of similar ethnicity and those attending regular health checkups camp/or participating in prostate cancer screening program were recruited as controls. None of the controls had any history of cancer. Controls were taken in age range 40-80 years to match the age of patients. The total PSA levels were determined in controls and BPH patients using CanAg PSA ELISA kits (Fugirebio, Sweden). Control individuals with PSA levels [4.0 ng/ml or positive DRE were excluded. The study protocol was approved by ethical committee of the Institute. The subjects were personally interviewed and information collected on alcohol consumption and tobacco intake. Participants were also questioned about their tobacco chewing habits and grouped into non tobacco users and tobacco users. Data on smoking habits were collected by asking whether they had smoked 20 packs of cigarettes or more in their lifetimes and, if yes, whether they currently smoke or had smoked in the past. A subject was considered as former smoker if he had not smoked for past 1 year.
DNA Extraction and Genotyping
Genomic DNA was extracted from peripheral blood mononuclear cells using salting out method [4] . PCR method used for genotyping with their respective position and reference is given in Table 1 .
Quality Control
To control genotyping errors 10% of the samples and were re-genotyped by other lab personal for another study. We found 99% concordance in re-genotyping results.
Statistical Analysis
The sample size was calculated and found to be adequate using QUANTO software, version 1.0 (http://hydra.usc. edu/exe) for the genetic marker. Sample size achieved 80% of the statistical power to consider odds ratio (OR) above 2 and below 0.5. A two tailed P value of less than 0.05 was considered statistically significant. Chi-square (v 2 ) analysis was used to assess deviation from Hardy-Weinberg's Equilibrium. Association of cytokine genotypes with risk of BPH was analyzed by unconditional logistic regression test. Patients and controls were used as dependent variable and genotypes, age, cigarette smoking, tobacco chewing 
TNF-A -863 C to A ARMS-PCR -Grutters et al. [7] TNF-A -1031 T to C ARMS-PCR -Grutters et al. [7] IFN-G ?874
IL-10 -1082 G to A ARMS-PCR -Perrey et al. [10] IL-10 -819 C to T ARMS-PCR -Perrey et al. [10] TGF-B ?28 Codon 10 T to C ARMS-PCR -Kruit et al. [11] and alcohol consumption were used as covariates. Risk was expressed as OR with 95% CI (confidence intervals). Wild type genotype/allele/haplotype was of TNF-A promoter polymorphism were taken as reference in risk analysis. ORs were also adjusted for the confounding factors like age, cigarette smoking, tobacco chewing and alcohol consumption by binary logistic regression.
Haplotype Analysis
Haplotypes of each individual consisting of four single nucleotide polymorphisms (SNPs) in TNF-A promoter and IL-10 promoter were constructed and their frequencies were assessed using the maximum-likelihood method, employing an expectation-maximization algorithm through software Arlequin ver. 2.0. Statistical significance was taken if the P \ 0.05. All statistical analyses were performed with the SPSS ver. 11.5 (SPSS Inc, Chicago, USA) statistical software package. Bonferroni correction was considered when making multiple gene comparison.
Results

Demographic Details
The demographic and clinical details are presented in Table 2 . There was no statistical difference between age of controls (60.7 ± 8.4 years) and cases (62.2±8.9 years) PSA concentration in controls exhibited significant difference (2.1 ± 1/0 ng/ml) and cases (9.3 ± 6.5 ng/ml). Higher percentage of smokers in BPH patients (39.7%) was depicted as compared to the controls (21.5%) Our results illustrated 2.4 fold risk for susceptibility to BPH in comparison to those who did not smoke (OR 2.4, P = 0.001).
Tobacco chewers and alcohol consumers, however, exhibited no significant difference between case and controls.
Pro-inflammatory Cytokines Gene Variants and Risk for Susceptibility to Benign Prostate Hyperplasia
All the genotypes were in concordance with HardyWeinberg equilibrium. Genotypic and allelic frequency distribution is shown in Table 3 . IL-1B promoter polymorphism illustrated significant difference between cases and controls (P 0.0004). Logistic regression analysis shows that CT ? TT genotype of IL-1B was associated with protective effect for BPH (OR 0.39, 95% CI 0.22-0.68, P 0.001). IL-1B T allele alone was protective for BPH (OR 0.66, 95% CI 0.49-0.84, P 0.004). Genotypic frequency distribution of other pro-inflammatory markers did not show any significant difference. However, frequency of TNF-A -1031C allele was significantly higher in patients in comparison to controls (P \ 0.0001). C allele also demonstrated to be risk factor for BPH (OR 1.89, 95% CI 1.41-2.53, P \ 0.0001). Other variants of TNF-A and IFN-G did not demonstrate any risk for BPH. As the four polymorphisms in TNF-A region were in same haplotye, risk for each haplotype was also assessed. Haplotype frequency was calculated among BPH cases and controls using genotyping data of four locus of TNF-A gene (TNF-A -1031, -863, -857, -308) (Fig. 1) . We observed risk associated with -1031C, -863C, -857C, -308G (C-C-C-G: OR 1.83, 95% CI 1.25-2.69, P 0.002) and C-C-T-G (OR 2.15, 95% CI 1.07-4.31, P 0.031) haplotypes associated with increased risk for BPH.
Anti-inflammatory Cytokines Gene Variants and Risk for Susceptibility to Benign Prostate Hyperplasia
All the anti-inflammatory genotypes were in HardyWeinberg equilibrium. 
Discussion
Inflammation is emerging as an important factor in the etiopathogenesis of BPH [12] . The present case-control study sought to determine the existence of a possible association between the polymorphisms of cytokine genes with BPH. IL-1B is pro-inflammatory cytokine and it has been earlier investigated that levels of IL-1B are up-regulated in BPH tissues [13] . Our results illustrated that IL-1B T allele to have a protective effect for BPH. The results also demonstrate that both the T carrying genotypes to be associated to be protective for BPH. When the comparison demonstrated that promoter polymorphisms in IL-1 B promoter region have no significant difference between IPSS scores, peak urinary flow rates, prostate size, and acute urinary retention, when homozygous wild type was compared to heterozygous and homozygous mutant [14] . Previous transactivation studies suggested that TNF-A -1031 was a regulatory site for TNF-A transcription and TNF-A -1031C allele enhanced gene transcription. Increased transcription of TNF-A gene resulted in TNF-a overproduction, which perpetuated a chronic inflammatory state and therefore higher risk for BPH [15] . Our results complement the studies reported by Higuschi et al. suggesting TNF-A -1031C allele to be at risk for BPH. Mak et al. reported TNF-A -863A allele to be associated with a decreased basal transcription rate of TNF-a. since TNF-863C/A, is situated at the border of a 10-bp sequence (GGGGACCCCC) showing high similarity to the consensus sequence of nuclear factor-jB (NF-jB) binding site [16] . However, our results show BPH with TNF-A -863 A allele to be protective. Furthermore, transcription factor OCT1 was reported to bind only TNF-857T but not TNF-857C [17] . OCT1 can physically interact with NF-jB and thus inhibit the transactivating activity of NF-jB. In the TNF-a signaling pathway, NF-jB is activated by TNF-a which subsequently stimulates the production of other cytokines such as IL-1, IL-6, and TNF-a itself. Therefore, ablating the activity of NF-jB can decrease the production of TNF-a and other downstream effectors. Many studies have also shown TNF-A variant -308 A allele to be associated with over expression of TNF. No association, however, of TNF-A -857 C [ T and TNF-A -308 G [ A polymorphism was observed with the risk of BPH.
The haplotypes TNF-A -1031C-863C-857C-308G and -1031T-863A-857C-308G demonstrated more than 50% frequency in patients as well as controls which was similar to that observed by a Korean study [18] . TNF-A -1031C-863C-857C-308G haplotype revealed increased risk for BPH by 50%. Susceptibility to BPH was, [20] . Though, this association may be because of low sample size of the study (41 PCa patients and 100 controls). Our results demonstrate no association of IL-1RA VNTR polymorphism with risk of BPH. However, our earlier studies have demonstrated its association with BPH, however, this may be low sample size (BPH 92 and control 128) [21] . Moreover, a recent study from North India studying the therapeutic aspect of various drugs, like alpha-adrenergic inhibitor plus 5-alphareductase inhibitor, which are required for treatment of BPH have shown that IL-1RA VNTR variants do not play a significant role in therapeutic response to these drugs [22] . Similarly a study from North India demonstrated that IL-4 VNTR polymorphism influences the therapeutic response of patients [22] . Our results demonstrate that presence of B2 allele of IL-4 VNTR to be protective for susceptibility of BPH. Surprisingly, comparison in cigarette smokers and tobacco chewers also demonstrated protective effect for BPH susceptibility if B2 allele was present in a genotype. However, this may be due to low sample size in these groups. Our results clearly imply that high producer genotype of IL-4 allele is protective for BPH.
Interleukin-10 (IL-10) is a recently described pteiotropic cytokine secreted mainly by type 2 helper T cells. We observed twofold increased risk associated with GA ? AA genotype carriers of IL-10 -1082 gene polymorphism, however, the risk was marginally significant (P 0.048). We did not observe any risk associated with IL-10 -819 gene polymorphism. In haplotype analysis we identified all the four haplotype in significant numbers. Haplotype IL-10 -819C -1082A (C-A) present in significantly higher frequency in BPH patients (31.3%) in comparison to controls (24.8%). C-A haplotype demonstrated moderated increase in risk for BPH (OR 1.59, P 0.027). Our results clearly reveal that IL-10 gene polymorphisms play an important role in etiology of benign prostate hyperplasia.
To the best of our knowledge and extensive literature search, this is perhaps the first study depicting the association of IL-6 -174, IFN-G ?874, TNF-A -1031, TNF-A -863, IL-10 -1082, IL-10 -819 and TGF-B ?28, polymorphism with BPH risk. The findings of this study thus indicated that TNF-A variants in the promoter region, susceptible to increased TNF production-may exert significant influence on BPH risk. Our results illustrated that TNF-A -1031 and -863 polymorphisms play an important role in the pathogenesis of BPH, however, the mechanism still remains to be elucidated Haplotype analysis revealed that TNF-A -1031C-863C-857C-308G and -1031T-863A-857C-308G may be associated with BPH risk. Moreover our results also convincingly illustrate role of IL-1B -511 and IL-10 -1082 in risk for BPH.
